Interventional Cardiology Therapies — Net Sales
Boston Scientific Interventional Cardiology Therapies — Net Sales decreased by 6.2% to $686.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 3.8%, from $661.00M to $686.00M. Over 3 years (FY 2021 to FY 2024), Interventional Cardiology Therapies — Net Sales shows an upward trend with a 6.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing demand for the company's cardiac products and successful adoption of new interventional technologies, while a decrease may signal increased competition, pricing pressure, or a slowdown in elective cardiac procedures.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices and technologies specifically design...
Peer comparison
Comparable to cardiovascular segment revenues reported by major medical device competitors like Abbott Laboratories, Medtronic, and Edwards Lifesciences.
bsx_segment_interventional_cardiology_therapies_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $574.00M | $534.00M | $575.00M | $544.00M | $574.00M | $549.00M | $561.00M | $591.00M | $629.00M | $583.00M | $614.00M | $652.00M | $665.00M | $661.00M | $667.00M | $697.00M | $731.00M | $686.00M |
| QoQ Change | — | -7.0% | +7.7% | -5.4% | +5.5% | -4.4% | +2.2% | +5.3% | +6.4% | -7.3% | +5.3% | +6.2% | +2.0% | -0.6% | +0.9% | +4.5% | +4.9% | -6.2% |
| YoY Change | — | — | — | — | +0.0% | +2.8% | -2.4% | +8.6% | +9.6% | +6.2% | +9.4% | +10.3% | +5.7% | +13.4% | +8.6% | +6.9% | +9.9% | +3.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's interventional cardiology therapies — net sales?
- Boston Scientific (BSX) reported interventional cardiology therapies — net sales of $686.00M in Q3 2025.
- How has Boston Scientific's interventional cardiology therapies — net sales changed year-over-year?
- Boston Scientific's interventional cardiology therapies — net sales increased by 3.8% year-over-year, from $661.00M to $686.00M.
- What is the long-term trend for Boston Scientific's interventional cardiology therapies — net sales?
- Over 3 years (2021 to 2024), Boston Scientific's interventional cardiology therapies — net sales has grown at a 6.2% compound annual growth rate (CAGR), from $2.21B to $2.65B.
- What does interventional cardiology therapies — net sales mean?
- The total revenue earned from selling medical devices used in minimally invasive heart and vascular procedures.